Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Compounding: How Does FDA Expand Oversight Without Legislation?

Executive Summary

After House Republicans indicate legislation expanding agency’s oversight of compounding is unlikely, FDA could consider other regulatory options, like changing internal policies or hoping a court clarifies its regulatory authority.

You may also be interested in...

Compounding: FDA Stepping Up Enforcement With Warning Letters?

FDA calls North Carolina compounder’s products misbranded and adulterated after the company did not receive valid prescriptions for a number of products it made and agency found several GMP violations.

Rep. Griffith’s Compounding Draft Ties FDA Inspections To State Reporting

Rep. Griffith circulates a discussion draft with new procedures for states to tell FDA when they have found problems at a compounder, but only then could the agency inspect the facility.

Large Compounders’ Reporting Requirements Would Move Closer To Manufacturers’ In Senate Bill

Compounding manufacturers would have to report adverse events and quality problems much like traditional drug and biologic makers as a Senate committee moves toward mark up of legislation.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts